Validation of Turkish psoriatic arthritis screening tool for psoriatic arthritis: A cross-sectional comparative study

Basit Öğe Kaydı
dc.contributor.authorBaşar Kılıç, Şeyma
dc.contributor.authorKulu, Huzeyfe
dc.contributor.authorSalman, Hüseyin
dc.contributor.authorBektaş, Murat
dc.date.accessioned2025-09-17T12:40:44Z
dc.date.available2025-09-17T12:40:44Z
dc.date.issued2025
dc.departmentTıp Fakültesi
dc.description.abstractPsoriasis (PsO) is a chronic immune-mediated disease that affects the skin and nails. Several screening tools such as psoriasis epidemiology screening tool, psoriatic arthritis screening and evaluation, early arthritis for psoriatic patients (EARP), STRIPP, SIPAS, and TOPAS have been developed and validated for identifying patients with suspected psoriatic arthritis (PsA) in dermatology clinics. Herein, we aim to validate and evaluate the performance of TurPAS in patients with PsO compared to the EARP questionnaire. This cross-sectional study was carried out in collaboration between dermatology and rheumatology clinics at Aksaray University Hospital, a tertiary referral center. All patients were examined for dermatologic aspects in the dermatology outpatient clinic and TurPAS and EARP questionnaires were performed by the same dermatologist. The patients who met the CASPAR criteria were classified as PsA in addition to appropriate clinical findings. In our study, 119 patients (n=72; 60.5% female) with PsO were included. Mean±standard deviation age of the patients was 44.9±14.3 (range; 18-83) years and the median (IQR) PsO duration was 10 (14) years. Median (IQR) TurPAS and EARP scores were 2 (3) and 3 (5), respectively. Overall, 39 patients (32.8%) met the CASPAR criteria and were classified as PsA. The best diagnostic accuracy was observed in≥3 positive items with 82% and 70% sensitivity and specificity (positive predictive value: 57.1%, negative predictive value: 89%, likelihood ratio: 2.7, diagnostic accuracy: 74%) for TurPAS and≥4 items with 74.4% and 86.3% (positive predictive value: 72.5%, negative predictive value: 87.3%, likelihood ratio: 5.4, diagnostic accuracy: 82.4%) for EARP. In our study, approximately one-third of patients with PsO were diagnosed as PsA. TurPAS had acceptable diagnostic performance compared to the EARP questionnaire. © 2025 the Author(s).
dc.identifier.doi10.1097/MD.0000000000044013
dc.identifier.issn00257974
dc.identifier.issue35
dc.identifier.pmid40898568
dc.identifier.scopus2-s2.0-105014600418
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000044013
dc.identifier.urihttps://hdl.handle.net/20.500.12451/14442
dc.identifier.volume104
dc.identifier.wosWOS:001470410100010
dc.identifier.wosqualityQ1
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.institutionauthorBaşar Kılıç, Şeyma
dc.institutionauthorKulu, Huzeyfe
dc.institutionauthorSalman, Hüseyin
dc.institutionauthorBektaş, Murat
dc.institutionauthorid0000-0003-3312-6630
dc.institutionauthorid0000-0002-1788-3837
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofMedicine (United States)
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectARP
dc.subjectPsoriasis
dc.subjectPsoriatic Arthritis
dc.subjectPsoriatic Arthritis Screening Tool
dc.subjectTurPAS
dc.titleValidation of Turkish psoriatic arthritis screening tool for psoriatic arthritis: A cross-sectional comparative study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
kilic-seyma basar-2025.pdf
Boyut:
823.47 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu